Patrick Flume to Europe
This is a "connection" page, showing publications Patrick Flume has written about Europe.
Connection Strength
0.420
-
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respir Med. 2021 07; 9(7):733-746.
Score: 0.171
-
US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. J Cyst Fibros. 2016 Mar; 15(2):139-40.
Score: 0.122
-
ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018 03; 17(2):153-178.
Score: 0.035
-
Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. 2017 06; 49(6).
Score: 0.033
-
Current strategies for the long-term assessment, monitoring, and management of cystic fibrosis patients treated with CFTR modulator therapy. J Cyst Fibros. 2017 01; 16(1):163-164.
Score: 0.032
-
European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros. 2014 May; 13 Suppl 1:S23-42.
Score: 0.027